SecBot SecBot
8-K ·Filed Jun 22, 2026

ORIC

Oric Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001193125-26-277511
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine governance filing with no immediate trading catalyst. The reduced evergreen provision (5% to 4%) marginally lowers future dilution risk, but the impact is negligible for near-term price action. Monitor the next quarterly filing for any changes in share count or compensation expense.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.91
T+0 close · Jun 22, 2026 · via day close
Latest settled
+40.74%
T+60 · $12.54
Vs SPY
+37.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 23 $8.91entry
  2. T+1 · 5mo ago +5.84%α +5.88% · $9.43
  3. T+5 · 5mo ago +13.97%α +12.96% · $10.16
  4. T+20 · 4mo ago +16.95%α +15.79% · $10.42
  5. T+60 · 2mo ago +40.74%α +37.49% · $12.54
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ORIC Pharmaceuticals filed an 8-K reporting the stockholder-approved amendment and restatement of its 2020 Equity Incentive Plan at the June 18, 2026 annual meeting. Key changes include reducing the annual evergreen increase from 5% to 4% of outstanding shares (removing the 2,656,500-share cap) and eliminating the ability to implement an exchange program. The filing also reports the re-election of directors Jacob M. Chacko, M.D. and Mardi C. Dier, ratification of KPMG as auditor, and an advisory vote supporting annual say-on-pay frequency. This is a routine governance filing with no material financial impact.

Key Facts

  • Stockholders approved the amended and restated 2020 Equity Incentive Plan with 61,228,918 votes for, 27,264,875 against, and 1,212,463 abstentions.
  • The annual evergreen provision was amended to reduce the annual increase from 5% to 4% of outstanding shares, removing the prior fixed cap of 2,656,500 shares.
  • The plan now caps incentive stock option issuance at 10,000,000 shares.
  • The administrator's ability to implement an exchange program (cancelling/re-pricing underwater options) was eliminated.
  • Directors Jacob M. Chacko, M.D. (89,298,150 for) and Mardi C. Dier (82,007,899 for) were re-elected as Class III directors.
  • KPMG LLP was ratified as independent auditor for FY2026 (94,536,096 for, 34,641 against).
  • Advisory vote on executive compensation passed with 88,453,809 for, 1,250,074 against.
  • Stockholders selected 'every one year' as the frequency for future advisory votes on executive compensation (89,392,979 for one year).
  • 94,571,281 shares (91.36% of outstanding) were represented at the meeting.

Financial Impact

No financial figures reported. The plan amendment reduces potential annual dilution from 5% to 4% of outstanding shares, a modest reduction in future equity compensation capacity.

dilutionequity compensation

Risk Factors

  • The 27.3 million 'against' votes on the equity plan (29% of votes cast) indicate notable shareholder dissent on compensation structure.
  • No financial results or guidance were provided in this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-277511
Document: d103876d8k.htm0001193125-26-277511
Document: 0001193125-26-277511-index-headers.html0001193125-26-277511
Document: 0001193125-26-277511-index.html0001193125-26-277511
Document: 0001193125-26-277511.txt0001193125-26-277511

Track record

12 reports on ORIC

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today Press Release Neutral 5/10 Entry $7.52 Now $7.52 −0.00% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $7.59 Now $7.52 −0.92% settles Nov 23
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.72 Now $7.52 −2.59% settles Nov 23
  4. Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $8.91 Now $7.52 −15.60% settles Nov 17
  5. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $13.17 to $9.24 Now $7.52 −42.90% ▼ −29.84% −29.28% vs SPY
  6. Oct 5, 20266w ago Press Release Bullish 6/10 Entry $11.98 to $11.31 Now $7.52 −37.23% ▼ −5.59% −5.45% vs SPY
  7. Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $12.49 to $11.81 Now $7.52 −39.79% ▼ −5.44% −5.87% vs SPY
  8. Aug 3, 202615w ago Press Release Neutral 5/10 Entry $13.47 to $13.73 Now $7.52 −44.17% ▲ +1.93% +2.03% vs SPY
  9. Jun 22, 202621w ago 8-K Neutral 3/10 Viewing Entry $8.91 to $10.16 Now $7.52 −15.60% ▲ +13.97% +12.96% vs SPY
  10. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $7.82 to $8.63 Now $7.52 −3.84% ▲ +10.36% +9.92% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 22, 2026